Table 3.

Treatment-related adverse events.

AEs	TACE+L n=91n, (%)		TACE+L+PD-1 n=75n, (%)
	Any Grade	≥ Grade 3	Any Grade	≥ Grade 3
Hypertension	11 (12.1)	3 (3.3)	19 (25.3)	6 (8.0)
Fatigue	10 (10.1)	2 (2.2)	10 (13.3)	4 (5.3)
Diarrhea	7 (7.7)	0 (0)	7 (9.3)	4 (5.3)
Decreased appetite	8 (8.8)	2 (2.2)	8 (10.7)	3 (4.0)
Nausea	7 (7.7)	0 (0)	7 (9.3)	3 (4.0)
Palmar-plantar Erythrodysesthesia syndrome	1 (1.1)	0 (0)	4 (5.3)	1 (1.3)
Proteinuria	0 (0)	0 (0)	1 (1.3)	0 (0)
Abnormal liver function	0 (0)	0 (0)	2 (2.6)	1 (1.3)
Thrombocytopenia	0 (0)	0 (0)	1 (1.3)	0 (0)
Abdominal pain	0 (0)	0 (0)	1 (1.3)	1 (1.3)
Hypothyroidism	0 (0)	0 (0)	1 (1.3)	0 (0)
Rash	1 (1.1)	0 (0)	1 (1.3)	0 (0)

TACE, transarterial chemoembolization; PD-1, anti-PD-1 blockade.